

Pulmonary Drugs-Europe Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/P9B6AF4FCB5MEN.html

Date: May 2018

Pages: 146

Price: US\$ 3,480.00 (Single User License)

ID: P9B6AF4FCB5MEN

Abstracts

Report Summary

Pulmonary Drugs-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Pulmonary Drugs industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Pulmonary Drugs 2013-2017, and development forecast 2018-2023

Main market players of Pulmonary Drugs in Europe, with company and product introduction, position in the Pulmonary Drugs market

Market status and development trend of Pulmonary Drugs by types and applications Cost and profit status of Pulmonary Drugs, and marketing status Market growth drivers and challenges

The report segments the Europe Pulmonary Drugs market as:

Europe Pulmonary Drugs Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany
United Kingdom
France
Italy
Spain



Benelux

Russia

Europe Pulmonary Drugs Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Inhaled Corticosteroids (ICS)

Long-Acting Beta2-Agonists (LABA)

Antihistamine

Vasodilators

Short-Acting Beta2-Agonists (SABA)

Anticholinergics

Combination Drugs

MAbs

Enzymes

Antibiotics & Antileukotrienes

Europe Pulmonary Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis

Europe Pulmonary Drugs Market: Players Segment Analysis (Company and Product introduction, Pulmonary Drugs Sales Volume, Revenue, Price and Gross Margin):

AstraZeneca plc

Bayer AG?

Teva Pharmaceutical Industries Ltd.?

Actelion Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd.

Merck & Co., Inc.

Novartis AG

GlaxoSmithKline plc

Sunovion Pharmaceuticals, Inc.



In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF PULMONARY DRUGS

- 1.1 Definition of Pulmonary Drugs in This Report
- 1.2 Commercial Types of Pulmonary Drugs
 - 1.2.1 Inhaled Corticosteroids (ICS)
 - 1.2.2 Long-Acting Beta2-Agonists (LABA)
 - 1.2.3 Antihistamine
 - 1.2.4 Vasodilators
 - 1.2.5 Short-Acting Beta2-Agonists (SABA)
 - 1.2.6 Anticholinergics
 - 1.2.7 Combination Drugs
 - 1.2.8 MAbs
 - 1.2.9 Enzymes
 - 1.2.10 Antibiotics & Antileukotrienes
- 1.3 Downstream Application of Pulmonary Drugs
 - 1.3.1 Asthma & COPD
 - 1.3.2 Allergic Rhinitis
 - 1.3.3 Pulmonary Arterial Hypertension
- 1.3.4 Cystic Fibrosis
- 1.4 Development History of Pulmonary Drugs
- 1.5 Market Status and Trend of Pulmonary Drugs 2013-2023
 - 1.5.1 EMEA Pulmonary Drugs Market Status and Trend 2013-2023
 - 1.5.2 Regional Pulmonary Drugs Market Status and Trend 2013-2023

CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Pulmonary Drugs in EMEA 2013-2017
- 2.2 Consumption Market of Pulmonary Drugs in EMEA by Regions
- 2.2.1 Consumption Volume of Pulmonary Drugs in EMEA by Regions
- 2.2.2 Revenue of Pulmonary Drugs in EMEA by Regions
- 2.3 Market Analysis of Pulmonary Drugs in EMEA by Regions
 - 2.3.1 Market Analysis of Pulmonary Drugs in Europe 2013-2017
 - 2.3.2 Market Analysis of Pulmonary Drugs in Middle East 2013-2017
 - 2.3.3 Market Analysis of Pulmonary Drugs in Africa 2013-2017
- 2.4 Market Development Forecast of Pulmonary Drugs in EMEA 2018-2023
- 2.4.1 Market Development Forecast of Pulmonary Drugs in EMEA 2018-2023
- 2.4.2 Market Development Forecast of Pulmonary Drugs by Regions 2018-2023



CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES

- 3.1 Whole EMEA Market Status by Types
 - 3.1.1 Consumption Volume of Pulmonary Drugs in EMEA by Types
 - 3.1.2 Revenue of Pulmonary Drugs in EMEA by Types
- 3.2 EMEA Market Status by Types in Major Countries
 - 3.2.1 Market Status by Types in Europe
 - 3.2.2 Market Status by Types in Middle East
 - 3.2.3 Market Status by Types in Africa
- 3.3 Market Forecast of Pulmonary Drugs in EMEA by Types

CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Pulmonary Drugs in EMEA by Downstream Industry
- 4.2 Demand Volume of Pulmonary Drugs by Downstream Industry in Major Countries
- 4.2.1 Demand Volume of Pulmonary Drugs by Downstream Industry in Europe
- 4.2.2 Demand Volume of Pulmonary Drugs by Downstream Industry in Middle East
- 4.2.3 Demand Volume of Pulmonary Drugs by Downstream Industry in Africa
- 4.3 Market Forecast of Pulmonary Drugs in EMEA by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF PULMONARY DRUGS

- 5.1 EMEA Economy Situation and Trend Overview
- 5.2 Pulmonary Drugs Downstream Industry Situation and Trend Overview

CHAPTER 6 PULMONARY DRUGS MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA

- 6.1 Sales Volume of Pulmonary Drugs in EMEA by Major Players
- 6.2 Revenue of Pulmonary Drugs in EMEA by Major Players
- 6.3 Basic Information of Pulmonary Drugs by Major Players
 - 6.3.1 Headquarters Location and Established Time of Pulmonary Drugs Major Players
 - 6.3.2 Employees and Revenue Level of Pulmonary Drugs Major Players
- 6.4 Market Competition News and Trend
 - 6.4.1 Merger, Consolidation or Acquisition News
 - 6.4.2 Investment or Disinvestment News
 - 6.4.3 New Product Development and Launch



CHAPTER 7 PULMONARY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

- 7.1 AstraZeneca plc
 - 7.1.1 Company profile
 - 7.1.2 Representative Pulmonary Drugs Product
 - 7.1.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca plc
- 7.2 Bayer AG?
 - 7.2.1 Company profile
 - 7.2.2 Representative Pulmonary Drugs Product
- 7.2.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Bayer AG?
- 7.3 Teva Pharmaceutical Industries Ltd.?
 - 7.3.1 Company profile
 - 7.3.2 Representative Pulmonary Drugs Product
 - 7.3.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Teva

Pharmaceutical Industries Ltd.?

- 7.4 Actelion Pharmaceuticals, Inc.
 - 7.4.1 Company profile
 - 7.4.2 Representative Pulmonary Drugs Product
- 7.4.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Actelion Pharmaceuticals, Inc.
- 7.5 Boehringer Ingelheim GmbH
 - 7.5.1 Company profile
 - 7.5.2 Representative Pulmonary Drugs Product
- 7.5.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH
- 7.6 F. Hoffmann-La Roche Ltd.
 - 7.6.1 Company profile
 - 7.6.2 Representative Pulmonary Drugs Product
- 7.6.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of F. Hoffmann-La Roche Ltd.
- 7.7 Merck & Co., Inc.
 - 7.7.1 Company profile
 - 7.7.2 Representative Pulmonary Drugs Product
 - 7.7.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Merck & Co., Inc.
- 7.8 Novartis AG
 - 7.8.1 Company profile
- 7.8.2 Representative Pulmonary Drugs Product



- 7.8.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Novartis AG
- 7.9 GlaxoSmithKline plc
 - 7.9.1 Company profile
 - 7.9.2 Representative Pulmonary Drugs Product
- 7.9.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
- 7.10 Sunovion Pharmaceuticals, Inc.
 - 7.10.1 Company profile
 - 7.10.2 Representative Pulmonary Drugs Product
- 7.10.3 Pulmonary Drugs Sales, Revenue, Price and Gross Margin of Sunovion Pharmaceuticals, Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PULMONARY DRUGS

- 8.1 Industry Chain of Pulmonary Drugs
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF PULMONARY DRUGS

- 9.1 Cost Structure Analysis of Pulmonary Drugs
- 9.2 Raw Materials Cost Analysis of Pulmonary Drugs
- 9.3 Labor Cost Analysis of Pulmonary Drugs
- 9.4 Manufacturing Expenses Analysis of Pulmonary Drugs

CHAPTER 10 MARKETING STATUS ANALYSIS OF PULMONARY DRUGS

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
- 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy
 - 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION



CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference



I would like to order

Product name: Pulmonary Drugs-Europe Market Status and Trend Report 2013-2023

Product link: https://marketpublishers.com/r/P9B6AF4FCB5MEN.html

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/P9B6AF4FCB5MEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970